Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 230-601-5 | CAS number: 7214-18-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in chemico
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- From 17 November 2021 to 16 February 2022
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 022
- Report date:
- 2022
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 442C (In Chemico Skin Sensitisation Assays addressing the Adverse Outcome Pathway key event on covalent binding to proteins)
- Version / remarks:
- 14 June 2021
- Qualifier:
- according to guideline
- Guideline:
- other: Direct Peptide Reactivity Assay (DPRA) for Skin Sensitization Testing, DB-ALM Protocol n°154
- Version / remarks:
- 12 January 2013
- GLP compliance:
- yes (incl. QA statement)
- Remarks:
- Bayerisches Landesamt für Gesundheit und Lebensmittelsicherheit, München, Germany
- Type of study:
- direct peptide reactivity assay (DPRA)
Test material
- Reference substance name:
- cis-2-tert-butylcyclohexan-1-ol
- EC Number:
- 230-601-5
- EC Name:
- cis-2-tert-butylcyclohexan-1-ol
- Cas Number:
- 7214-18-8
- Molecular formula:
- C10H20O
- IUPAC Name:
- cis-2-tert-butylcyclohexan-1-ol
- Test material form:
- solid
Constituent 1
In chemico test system
- Details of test system:
- other:
- Details on the study design:
- Preparation of the Test Item: The test item was freshly prepared immediately prior to use, unless stability data demonstrate the acceptability of storage. The test item was pre-weighed into a glass vial and was dissolved in an appropriate solvent previously determined in a pre-experiment. A stock solution with a concentration of 100 mM was prepared. A factor of 1.14 was used to correct for the purity of the test item.
Controls: Reference controls, co-elution controls and a positive control (PC) were set up in parallel to the test item in order to confirm the validity of the test.
- Positive Control : Cinnamic aldehyde was solved in acetonitrile and was used as positive control. A stock concentration of 100 mM was prepared and was included in every assay run for both peptides.
- Co-elution Control : Co-elution controls were set up in parallel to sample preparation but without the respective peptide solution. The controls were used to verify whether a test chemical absorbs at 220 nm and co-elutes with the cysteine or lysine peptide. The co-elution controls were prepared for every test item preparation and the positive control and were included in every assay run for both peptides.
- Reference Control : Reference controls (RCs) were set up in parallel to sample preparation in order to verify the validity of the test run.
- Reference control A was prepared using acetonitrile in order to verify the accuracy of the calibration curve for peptide quantification. Its replicates were injected in the beginning of each HPLC run.
- Reference control B was prepared using acetonitrile in order to verify the stability of the respective peptide over the analysis time. Its replicates were injected in the beginning and in the end of each HPLC run. Reference control C was set up for the test item and the positive control. RC C for the positive control was prepared using acetonitrile. RC C for the test item was the same as for the positive control because no (further) solvent was used. The RC C was used to verify that the solvent does not impact the percent peptide depletion (PPD). Additionally, reference control C was used to calculate PPD. The RC C was included in every assay run for both peptides and was injected together with the samples.
Peptides: 20.42 mg cysteine peptide with an amino acid sequence of Ac-RFAACAA were pre-weighed in a vial and dissolved in a defined volume (40 mL) of a phosphate buffer with pH 7.5 to reach a concentration of 0.667 mM. 20.66 mg lysine peptide with an amino acid sequence of Ac-RFAAKAA were pre-weighed in a vial and dissolved in a defined volume of ammonium acetate buffer with pH 10.2 (39.88 mL) to reach a concentration of 0.667 mM. All peptides used for this study were stored at -80 °C and protected from light. Peptides were thawed only immediately prior to use.
Dose Groups:
- Reference Control C (solvent control)
- Test Item: 100 mM stock solution
- Positive Control: 100 mM stock solution
Pre-Experiments:
- Solubility of the test item was determined prior to the main experiment and was tested at the highest final concentration applied in the study (100 mM). Solubility was investigated in the following solvents suitable for the test: acetonitrile
- The test item was completely soluble in acetonitrile, therefore, acetonitrile was chosen as suitable vehicle for the main experiments.
Experimental Procedure:
Incubation of the Test Item with the Cysteine and Lysine Peptide : The test item solutions were incubated with the cysteine and lysine peptide solutions in glass vials using defined ratios of peptide to test item (1:10 cysteine peptide, 1:50 lysine peptide). The reaction solutions were left in the dark at 25 ± 2.5 °C for 24 ± 2 h before running the HPLC analysis. Reference controls, co-elution controls as well as the positive control were set up in parallel.
Test item solutions were inspected on a visual basis for the formation of precipitates, turbidity and phase separation prior and after HPLC analysis. If a precipitate or phase separation was observed after the reaction period and prior to the HPLC analysis, samples might have been centrifuged at low speed (100 - 400x g) to force precipitates to the bottom of the vial. After the incubation period of 24 ± 2 h the test item was analysed in triplicate for both peptides using the following HPLC procedure.
Preparation of the HPLC Standard Calibration Curve :A standard calibration curve was generated for both, the cysteine and the lysine peptide. Peptide standards were prepared in a solution of 20% acetonitrile: 80% buffer (v/v) using phosphate buffer (pH 7.5) for the cysteine peptide and ammonium acetate buffer (pH 10.2) for the lysine peptide (dilution buffer (DB)). A serial dilution of the peptide stock solution (0.667 mM) using the respective DB was performed, resulting in 7 calibration solutions.
Data Analysis: The concentration of the cysteine and lysine peptide was determined in each sample from absorbance at λ = 220 nm, measuring the area of the appropriated peaks (peak area (PA)) and calculating the concentration of peptide using the linear calibration curves derived from the standard solutions. The percent peptide depletion (PPD) was calculated according to the following formula:
𝑃𝑃𝐷=(1−(𝑃𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑖𝑛 𝑡ℎ𝑒 𝑅𝑒𝑝𝑙𝑖𝑐𝑎𝑡𝑒 𝐼𝑛𝑗𝑒𝑐𝑡𝑖𝑜𝑛/𝑀𝑒𝑎𝑛 𝑃𝑒𝑝𝑡𝑖𝑑𝑒 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎 𝑖𝑛 𝑅𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝐶𝑜𝑛𝑡𝑟𝑜𝑙 𝐶))∗100
The absorbance at λ = 258 nm was also monitored for the samples of the test item and the reference controls as a co-elution control. The ratio of the peak areas (220 nm / 258 nm) was checked for consistency between reference control and test item samples. If this ratio was not consistent, a co-elution was assumed and the evaluation would be adjusted accordingly.
Acceptance Criteria: The run meets the acceptance criteria if:
- the standard calibration curve has a r² > 0.99,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is between 60.8% and 100% for the cysteine peptide and the maximum standard deviation (SD) for the positive control replicates is < 14.9%,
- the mean percent peptide depletion (PPD) value of the three replicates for the positive control is between 40.2% and 69.0% for the lysine peptide and the maximum SD for the positive control replicates is < 11.6%,
- the mean peptide concentration of the three reference controls A replicates is 0.50 ± 0.05 mM,
- the coefficient of variation (CV) of peptide peak areas for the six reference control B replicates and three reference control C replicates in acetonitrile is < 15.0%.
The results of the test item meet the acceptance criteria if:
- the maximum standard deviation (SD) for the test chemical replicates is < 14.9% for the cysteine percent depletion (PPD),
- the maximum standard deviation (SD) for the test chemical replicates is < 11.6% for the lysine percent depletion (PPD),
- the mean peptide concentration of the three reference controls C replicates in the appropriate solvent is 0.50 ± 0.05 mM. - Vehicle / solvent:
- acetonitrile
- Positive control:
- cinnamic aldehyde
Results and discussion
- Positive control results:
- The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 68.50%.
In vitro / in chemico
Resultsopen allclose all
- Key result
- Group:
- test chemical
- Run / experiment:
- mean
- Parameter:
- mean cystein depletion
- Value:
- 0.93 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Key result
- Group:
- test chemical
- Run / experiment:
- mean
- Parameter:
- mean lysine depletion
- Value:
- 0 %
- Vehicle controls validity:
- valid
- Negative controls validity:
- valid
- Positive controls validity:
- valid
- Outcome of the prediction model:
- no or minimal reactivity [in chemico]
- Other effects / acceptance of results:
- Both peptide runs and the test item results met the acceptance criteria of the test.
Any other information on results incl. tables
Precipitation and Phase Separation: For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for any of the samples. For the 100 mM stock solution of the test item turbidity was observed when diluted with the lysine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. Phase separation was observed for the samples of the test item (including the co-elution control). Samples were not centrifuged prior to the HPLC analysis.
Co-elution with the Peptide Peaks : No co-elution of the test item with any of the peptide peaks was observed.
To detect a co-elution of the test item with the peptide peak, a ratio of the 220 nm peak area and the 258 nm peak area was calculated too (peak purity indication). If the ratio of the control samples and the test item samples do not differ more than 10% from each other, no sign for a co-elution is given.
For the cysteine measurement the peak purity indication was < 10% (0.5 % test item replicate 1; 0.4 % test item replicate 2; 0.7 % test item replicate 3; mean: 0.3 %) and for the lysine measurement the peak purity indication was < 10% (0.3 % test item replicate 1; 0.8 % test item replicate 2; 0.3 % test item replicate 3; mean: 0.1 %).
Cysteine and Lysine Values of the Calibration Curve:
Sample | Cysteine Peptide | Lysine Peptide | ||
Peak Area | Peptide Concentration [mM] | Peak Area | Peptide Concentration [mM] | |
STD1 | 16.1350 | 0.5340 | 14.0090 | 0.5340 |
STD2 | 8.1080 | 0.2670 | 6.8920 | 0.2670 |
STD3 | 4.0320 | 0.1335 | 3.4080 | 0.1335 |
STD4 | 1.9610 | 0.0667 | 1.7000 | 0.0667 |
STD5 | 0.9660 | 0.0334 | 0.8720 | 0.0334 |
STD6 | 0.4700 | 0.0167 | 0.4500 | 0.0167 |
STD7 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Depletion of the Cysteine Peptide
Cysteine Peptide | ||||||
Sample | Peak Area | Peptide Conc. [mM] | Peptide Depletion [%] | Mean Peptide Depletion [%] | SD of Peptide Depletion [%] | CV of Peptide Depletion [%] |
Positive Control | 4.1070 | 0.1364 | 72.76 | 72.98 | 0.20 | 0.27 |
4.0500 | 0.1345 | 73.13 | ||||
4.0630 | 0.1350 | 73.05 | ||||
Test Item | 15.3380 | 0.5071 | 0.00 | 0.93 | 0.93 | 99.76 |
14.9340 | 0.4937 | 0.94 | ||||
14.7950 | 0.4891 | 1.86 |
Depletion of the Lysine Peptide:
Lysine Peptide | ||||||
Sample | Peak Area | Peptide Conc. [mM] | Peptide Depletion [%] | Mean Peptide Depletion [%] | SD of Peptide Depletion [%] | CV of Peptide Depletion [%] |
Positive Control | 4.6070 | 0.1770 | 63.94 | 64.03 | 0.07 | 0.11 |
4.5890 | 0.1763 | 64.09 | ||||
4.5940 | 0.1765 | 64.05 | ||||
Test Item | 12.8560 | 0.4919 | 0.00 | 0.00 | 0.00 | n/a |
12.8720 | 0.4925 | 0.00 | ||||
12.8620 | 0.4921 | 0.00 |
Categorization of the Test Item:
Prediction Model | Prediction Model 1 | Prediction Model 2 | ||||
Test Substance | Mean Peptide Depletion [%] | Reactivity Category | Prediction | Mean Peptide Depletion [%] | Reactivity Category | Prediction |
Test Item | -- | -- | -- | 0.93 | Minimal Reactivity | negative |
Positive Control | 68.50 | High Reactivity | positive | 72.98 | Moderate Reactivity | positive |
Applicant's summary and conclusion
- Interpretation of results:
- other: Not classified in accordance with EU CLP (EC no 1272/2008 and its amendments)
- Conclusions:
- In this study under the given conditions the test item showed minimal reactivity towards the cysteine peptide.
- Executive summary:
The study was conducted to determine the sensitising potential of Verdol according to the OECD Guideline 422C in compliance with GLP. Based on a molecular weight of 156.26 g/mol a 100 mM stock solution was prepared in acetonitrile. The test item solutions were tested by incubating the samples with the peptides containing either cysteine or lysine for 24 ± 2 h at 25 ± 2.5 °C. Subsequently samples were analysed by HPLC. All test item solutions were freshly prepared immediately prior to use.
For the 100 mM stock solution of the test item no turbidity or precipitation was observed when diluted with the cysteine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. No precipitation, turbidity or phase separation was observed for any of the samples. For the 100 mM stock solution of the test item turbidity was observed when diluted with the lysine peptide solution. After the 24 h ± 2 h incubation period but prior to the HPLC analysis samples were inspected for precipitation, turbidity or phase separation. Phase separation was observed for the samples of the test item (including the co-elution control). Samples were not centrifuged prior to the HPLC analysis.
Phase separation in the lysine experiment was observed. Therefore, the given peak areas and corresponding lysine peptide values can only be considered as an estimation of the peptide depletion and cannot be used for evaluation. Sensitising potential of the test item was predicted from the mean peptide depletion of the cysteine peptide by comparing the peptide concentration of the test item treated samples to the corresponding reference control C.
The 100 mM stock solution of the test item showed minimal reactivity towards the synthetic peptide. The mean depletion of the cysteine peptide was ≤ 13.89% (0.93%). The 100 mM stock solution of the positive control (cinnamic aldehyde) showed high reactivity towards the synthetic peptides. The mean depletion of both peptides was 68.50%. The controls confirmed the validity of the study for both, the cysteine and lysine run.
In this study under the given conditions the test item showed minimal reactivity towards the cysteine peptide.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.